XML 67 R33.htm IDEA: XBRL DOCUMENT v3.22.1
General (Details)
Mar. 16, 2021
shares
Dec. 14, 2020
Restructuring Cost and Reserve [Line Items]    
Reverse stock split conversion ratio 4  
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]    
Restructuring Cost and Reserve [Line Items]    
Number of ordinary shares represented by each ADS (in shares) 20  
Number of ADS issued and outstanding after the merger 12.86  
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member] | Former Chemomab Security Holders [Member]    
Restructuring Cost and Reserve [Line Items]    
Shareholding percentage immediately following the merger   90.00%
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member] | Security holders of Anchiano as of immediately prior to the merger [Member]    
Restructuring Cost and Reserve [Line Items]    
Shareholding percentage immediately following the merger   10.00%